HONG KONG – Chinese pharmaceutical firms have come a long way, transforming themselves from makers of active pharmaceutical ingredients (APIs) to innovative drug developers in a couple of decades.

TOKYO – A series of reforms over the past year by Japan’s PMDA have cut down approval times, improved the level of science regulators expected to review drug and medical device applications and helped Japanese authorities strengthen ties with their peers around the world. Those efforts, and others, are aimed at positioning the country as a regulatory leader in Asia.

HONG KONG – Chinese pharmaceutical firms have come a long way, transforming themselves from makers of active pharmaceutical ingredients (APIs) to innovative drug developers in a couple of decades. The secret sauce in that transformation has been investment in R&D.

TOKYO – A series of reforms over the past year by Japan’s PMDA have cut down approval times, improved the level of science regulators expected to review drug and medical device applications and helped Japanese authorities strengthen ties with their peers around the world. Those efforts, and others, are aimed at positioning the country as a regulatory leader in Asia.

HONG KONG – Rules imposed by Sharia Law are often a concern for individuals or small companies in underfunded sectors in the Middle East and North Africa (MENA) region, but they are less of an issue for cash-rich industries. The good news is that most biomedical companies in MENA fall under the latter category.

TOKYO – Japan is reaching out to drug developers from around the world to attract more innovative products and emerge as a regional leader in the field.

TOKYO – Japan is reaching out to drugmakers and developers from Asia and elsewhere, looking to attract more innovative products and emerge as a regional leader in the field.